MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain.
In animals, repeated administration of 3,4-methylenedioxymethamphetamine (MDMA) reduces markers of serotonergic activity and studies show similar serotonergic deficits in human MDMA users. Using proton-magnetic resonance spectroscopy ((1)H-MRS) at 11.7Tesla, we measured the metabolic neurochemical profile in intact, discrete tissue punches taken from prefrontal cortex, anterior striatum, and hippocampus of rats administered MDMA (5mg/kg IP, 4× q 2h) or saline and euthanized 7 days after the last injection. Monoamine content was measured with HPLC in contralateral punches from striatum and hippocampus to compare the MDMA-induced loss of 5HT innervation with constituents in the (1)H-MRS profile. When assessed 7 days after the last MDMA injection, levels of hippocampal and striatal serotonin (5HT) were significantly reduced, consistent with published animal studies. N-Acetylaspartate (NAA) levels were significantly increased in prefrontal cortex and not affected in anterior striatum or hippocampus; myo-inositol (INS) levels were increased in prefrontal cortex and hippocampus but not anterior striatum. Glutamate levels were increased in prefrontal cortex and decreased in hippocampus, while GABA levels were decreased only in hippocampus. The data suggest that NAA may not reliably reflect MDMA-induced 5HT neurotoxicity. However, the collective pattern of changes in 5HT, INS, glutamate and GABA is consistent with persistent hippocampal neuroadaptations caused by MDMA.
Perrine
Shane A
SA
Department of Psychiatry and Behavioral Neurosciences, Brain Research and Imaging Neuroscience Division, Wayne State University School of Medicine, Detroit, MI 48201, USA. sperrine@med.wayne.edu
Ghoddoussi
Farhad
F
Michaels
Mark S
MS
Hyde
Elisabeth M
EM
Kuhn
Donald M
DM
Galloway
Matthew P
MP
D000818:Animals; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D001923:Brain Chemistry / Q000187:drug effects* / Q000502:physiology; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000633:toxicity*
D012702:Serotonin Antagonists; D001224:Aspartic Acid; D012701:Serotonin; C000179:N-acetylaspartate; D018817:N-Methyl-3,4-methylenedioxyamphetamine
Neuroreport. 1999 Nov 26;10(17):3675-80
10619665
Magn Reson Imaging. 1998 Oct;16(8):969-79
9814780
Ann N Y Acad Sci. 2000 Sep;914:92-103
11085312
CNS Neurol Disord Drug Targets. 2007 Apr;6(2):127-40
17430150
NMR Biomed. 2001 Jun;14(4):278-83
11410946
AJNR Am J Neuroradiol. 1999 Oct;20(9):1619-27
10543631
Crit Rev Neurobiol. 2000;14(1):23-45
11253954
Synapse. 1998 Jun;29(2):183-92
9593108
Toxicol Appl Pharmacol. 1988 Jul;94(3):448-57
2456631
Drug Saf. 1996 Aug;15(2):107-15
8884162
J Neurosci. 1988 Aug;8(8):2788-803
2457659
Brain Res. 2003 Jun 6;974(1-2):127-33
12742630
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3127-33
8475050
Pharmacol Biochem Behav. 2008 Aug;90(2):198-207
18035407
MAGMA. 1998 Dec;7(2):95-114
9951770
Neuroscience. 2007 Mar 30;145(3):900-10
17293055
NMR Biomed. 2009 May;22(4):419-25
18985626
AJNR Am J Neuroradiol. 2002 Feb;23(2):231-7
11847047
Alcohol Clin Exp Res. 2008 Oct;32(10):1697-707
18631322
Eur Arch Psychiatry Clin Neurosci. 2001 Jun;251(3):114-6
11697571
Biosci Rep. 2007 Jun;27(1-3):69-85
17510789
J Neural Transm (Vienna). 1997;104(2-3):135-46
9203077
Pharmacol Biochem Behav. 2009 Mar;92(1):105-10
19032963
Psychol Med. 1995 Nov;25(6):1201-9
8637950
Addiction. 2005 Sep;100(9):1310-9
16128720
Neurosci Lett. 2004 May 20;362(2):113-6
15193766
J Pharmacol Exp Ther. 1987 Apr;241(1):338-45
2883295
Magn Reson Med. 1997 Jan;37(1):24-33
8978629
J Neurol Neurosurg Psychiatry. 1998 Oct;65(4):518-22
9771777
Synapse. 2002 Dec 1;46(3):199-205
12325046
Harv Rev Psychiatry. 2002 Jul-Aug;10(4):212-20
12119307
Neuropsychopharmacology. 2010 Jan;35(1):27-47
19675534
Schizophr Res. 1992 Oct;8(1):43-9
1329928
Neuropsychopharmacology. 2002 Mar;26(3):387-96
11850153
Psychopharmacology (Berl). 2001 Aug;157(1):82-8
11512047
Neurotox Res. 2001 Jan;3(1):85-99
15111263
Psychopharmacology (Berl). 2007 Jan;189(4):425-34
16470404
Neurosci Lett. 2004 Sep 9;367(3):349-54
15337264
Mitochondrion. 2008 Dec;8(5-6):396-413
18590986
J Magn Reson Imaging. 2003 Jan;17(1):11-9
12500270
Neuroscience. 2009 May 5;160(2):264-74
19236907
Neurotoxicol Teratol. 2007 Jul-Aug;29(4):466-75
17466488
J Neurosci. 1993 Mar;13(3):981-9
8441018
Ann N Y Acad Sci. 2008 Oct;1139:291-8
18991874
Annu Rev Physiol. 2003;65:401-27
12524459
Magn Reson Med. 1993 Dec;30(6):672-9
8139448
Brain Res. 1988 Apr 12;446(1):165-8
2897228
Neuroscience. 2008 Jan 24;151(2):533-43
18082974
Neuroscience. 1995 Dec;69(4):1095-1101
8848098
J Neurosci. 2001 Dec 15;21(24):9955-63
11739602
Psychopharmacology (Berl). 2007 Jan;189(4):575-6
17061108
Brain. 2008 Nov;131(Pt 11):2936-45
18842607
Psychiatry Res. 2007 Aug 15;155(3):179-88
17574394
Neuroscience. 1991;45(1):37-45
1754068
J Neuroimmune Pharmacol. 2008 Dec;3(4):203-17
18709468
J Neurol Sci. 2010 Mar 15;290(1-2):41-7
20060132
Lancet. 1998 Oct 31;352(9138):1433-7
9807990
J Pharmacol Exp Ther. 1987 Sep;242(3):911-6
2443644
Neuropsychopharmacology. 2005 Sep;30(9):1741-50
15841106
Neuropsychopharmacology. 2007 Feb;32(2):458-70
17077812
Magn Reson Med. 2009 Oct;62(4):868-79
19591201
Biol Psychiatry. 2001 Oct 1;50(7):550-4
11600108
Synapse. 2004 Sep 15;53(4):240-8
15266556
BMC Neurosci. 2008 Apr 17;9:39
18419818
Neurochem Int. 2007 Jan;50(2):386-94
17074420
Sci Pract Perspect. 2007 Apr;3(2):4-16
17514067
J Magn Reson Imaging. 1999 Oct;10(4):521-6
10508318
Cereb Cortex. 2000 Oct;10(10):974-80
11007548
Ann N Y Acad Sci. 2006 Aug;1074:365-76
17105934
Neuropsychopharmacology. 2006 Jul;31(7):1562-73
16292322
Am J Psychiatry. 2004 Jul;161(7):1181-9
15229049
Mov Disord. 2007 Feb 15;22(3):382-6
17216652
Psychopharmacol Bull. 2002 Spring;36(2):5-23
12397837
J Psychopharmacol. 2006 Mar;20(2):211-25
16510479
Pharmacol Rev. 2003 Sep;55(3):463-508
12869661
Psychopharmacology (Berl). 2007 Jan;189(4):539-56
16847678